Hana Ciferská

A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy

Jung‐Yoon Choe, Nenad Prodanović, Jaroslaw Niebrzydowski et al. · Annals of the Rheumatic Diseases · 2015 · 165 citations · Full text

Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study

Josef S Smolen, Jung‐Yoon Choe, Nenad Prodanović et al. · Annals of the Rheumatic Diseases · 2017 · 121 citations · Full text

Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety results

Josef S Smolen, Jung‐Yoon Choe, Nenad Prodanović et al. · Lara D. Veeken · 2017 · 54 citations · Full text

High mobility group box-1 (HMGB-1) in osteoarthritic cartilage.

T. Heinola, Vesa‐Petteri Kouri, Paul Clarijs et al. · PubMed · 2010 · 51 citations

C1q complement component and -antibodies reflect SLE activity and kidney involvement

Pavel Hořák, Zuzana Heřmanová, Josef Zadražil et al. · Clinical Rheumatology · 2005 · 45 citations

Immunology, C1q Complement Component, Pathology +16